| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
Purity: =98.36%
| Targets |
Suc-Gly-Pro-AMC targets fibroblast activation protein (FAP), a serine protease that is overexpressed in cancer-associated fibroblasts and is involved in tumor progression. The compound is a specific substrate for FAP and also reacts with recombinant porcine prolyl oligopeptidase. By serving as a substrate, it enables the measurement of FAP activity in biochemical and cellular assays.
|
|---|---|
| ln Vitro |
Suc-Gly-Pro-AMC is a fibroblast activation protein (FAP) specific substrate. Upon enzymatic cleavage by FAP, the compound releases the fluorescent molecule 7-amino-4-methylcoumarin (AMC), enabling researchers to monitor protease function through fluorescence-based assays. It can be used to study the activity of FAP and prolyl endopeptidase (PREP). The compound's specific kinetic parameters (Km, kcat) are not extensively documented.
|
| ln Vivo |
In vivo activity data for Suc-Gly-Pro-AMC are not applicable, as the compound is used as a substrate for in vitro biochemical assays rather than as a therapeutic agent. The compound is not intended for in vivo therapeutic applications. Its primary use is in research to measure FAP activity in biological samples. The compound may be used in ex vivo assays to measure FAP activity in tissue samples.
|
| Enzyme Assay |
The in vitro enzyme assay for Suc-Gly-Pro-AMC typically involves incubating the substrate with FAP enzyme or biological samples containing FAP activity. The assay is performed in buffer at physiological pH (7.4-8.0) and temperature (37°C). The release of AMC is monitored continuously or at specific time points using a fluorescence plate reader with excitation at ~380 nm and emission at ~460 nm. The compound is dissolved in DMSO and diluted in assay buffer.
|
| Cell Assay |
In vitro cellular assays for Suc-Gly-Pro-AMC typically involve treating FAP-expressing cells with the substrate. Cells are incubated with the substrate at concentrations ranging from 1 to 100 µM for 1-24 hours. The release of AMC is measured in the culture supernatant using a fluorescence plate reader. FAP activity is calculated based on the rate of AMC release. The compound is dissolved in DMSO and diluted in cell culture medium.
|
| Animal Protocol |
In vivo animal studies for Suc-Gly-Pro-AMC are not typically performed, as the compound is used as a substrate for in vitro assays rather than as a therapeutic agent. The compound may be used in ex vivo assays to measure FAP activity in tissue samples from animal models. For such applications, tissue homogenates are incubated with the substrate, and AMC release is measured fluorometrically.
|
| ADME/Pharmacokinetics |
Suc-Gly-Pro-AMC has a molecular weight of 429.42 g/mol and formula C21H23N3O7. Purity is typically 96%. Recommended storage is at -80°C, protected from light. The compound is soluble in DMSO. Detailed PK parameters are not applicable for this substrate.
|
| Toxicity/Toxicokinetics |
Suc-Gly-Pro-AMC is intended for research use only and is not approved for human therapeutic applications. As a substrate, it is generally considered to have low toxicity, but appropriate safety precautions should be taken when handling. Standard toxicity assessments would include acute toxicity and repeated-dose toxicity studies if required for specific applications.
|
| References | |
| Additional Infomation |
Suc-Gly-Pro-AMC (CAS 80049-85-0) is a fibroblast activation protein (FAP) specific substrate with a molecular weight of 429.42 g/mol and formula C21H23N3O7. It releases the fluorescent molecule 7-amino-4-methylcoumarin (AMC) upon enzymatic cleavage. The compound is also known as Suc-GP-AMC and is used to study FAP and prolyl endopeptidase (PREP) activity. Suc-Gly-Pro-AMC is not approved for clinical use.
|
| Molecular Formula |
C21H23N3O7
|
|---|---|
| Molecular Weight |
429.42322
|
| Exact Mass |
429.154
|
| CAS # |
80049-85-0
|
| PubChem CID |
21121742
|
| Appearance |
White to off-white solid powder
|
| Density |
1.416g/cm3
|
| Boiling Point |
707.1ºC at 760 mmHg
|
| Flash Point |
381.5ºC
|
| Index of Refraction |
1.615
|
| LogP |
1.413
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
794
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@@H]3CCCN3C(=O)CNC(=O)CCC(=O)O
|
| InChi Key |
NKEPCOOQNLGSLJ-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C21H23N3O7/c1-12-9-20(29)31-16-10-13(4-5-14(12)16)23-21(30)15-3-2-8-24(15)18(26)11-22-17(25)6-7-19(27)28/h4-5,9-10,15H,2-3,6-8,11H2,1H3,(H,22,25)(H,23,30)(H,27,28)/t15-/m0/s1
|
| Chemical Name |
4-[[2-[(2S)-2-[(4-methyl-2-oxochromen-7-yl)carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~232.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3287 mL | 11.6436 mL | 23.2872 mL | |
| 5 mM | 0.4657 mL | 2.3287 mL | 4.6574 mL | |
| 10 mM | 0.2329 mL | 1.1644 mL | 2.3287 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA